Get the Stockscreener App
7.65
0.33%
-0.00
After Hours:
7.78
0.13
+1.70%
Kura Oncology Inc stock is traded at $7.65, with a volume of 1.39M.
It is down -0.33% in the last 24 hours and up +22.39% over the past month.
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
See More
Previous Close:
$7.65
Open:
$7.69
24h Volume:
1.39M
Relative Volume:
0.99
Market Cap:
$664.00M
Revenue:
-
Net Income/Loss:
$-168.09M
P/E Ratio:
-3.5253
EPS:
-2.17
Net Cash Flow:
$-138.01M
1W Performance:
+1.94%
1M Performance:
+22.39%
6M Performance:
-3.24%
1Y Performance:
-62.22%
1-Day Range:
$7.475
$7.755
1-Week Range:
$6.95
$7.80
52-Week Range:
$5.41
$21.57
Kura Oncology Inc Stock (KURA) Company Profile
Name
Kura Oncology Inc
Sector
Industry
Phone
(858) 500-8800
Address
12730 HIGH BLUFF DRIVE, SUITE 400, SAN DIEGO, CA
Compare KURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KURA
Kura Oncology Inc
|
7.65 | 649.24M | 0 | -168.09M | -138.01M | -2.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
388.94 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.38 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
443.64 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
677.32 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
308.63 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Kura Oncology Inc Stock (KURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-06-25 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-24-24 | Initiated | UBS | Buy |
| Oct-14-24 | Downgrade | Stifel | Buy → Hold |
| Dec-22-23 | Initiated | Mizuho | Buy |
| Aug-11-23 | Initiated | BofA Securities | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| May-17-23 | Initiated | BTIG Research | Buy |
| Jan-31-23 | Initiated | Stifel | Buy |
| Jul-12-22 | Initiated | Cantor Fitzgerald | Overweight |
| Feb-15-22 | Initiated | Jefferies | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-07-20 | Reiterated | H.C. Wainwright | Buy |
| Dec-03-20 | Initiated | Stifel | Buy |
| Nov-05-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Initiated | Credit Suisse | Outperform |
| May-05-20 | Initiated | Barclays | Overweight |
| Jul-18-19 | Initiated | Deutsche Bank | Buy |
| Nov-09-18 | Initiated | Piper Jaffray | Overweight |
| Aug-01-18 | Initiated | H.C. Wainwright | Buy |
| Oct-13-16 | Resumed | Leerink Partners | Outperform |
| Jan-22-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-30-15 | Initiated | Oppenheimer | Outperform |
| Dec-16-15 | Initiated | Citigroup | Buy |
View All
Kura Oncology Inc Stock (KURA) Latest News
Using RSI to spot recovery in Kura Oncology Inc.Exit Point & Fast Gaining Stock Strategy Reports - Newser
Volume spikes in Kura Oncology Inc. stock – what they meanWeekly Market Summary & Free Safe Entry Trade Signal Reports - Newser
Tools to assess Kura Oncology Inc.’s risk profileWeekly Market Outlook & Weekly High Return Stock Opportunities - Newser
What data driven models say about Kura Oncology Inc.’s future2025 Year in Review & Risk Managed Investment Entry Signals - Newser
Published on: 2025-08-19 23:46:42 - Newser
Comparing Kura Oncology Inc. in custom built stock radarsWeekly Investment Recap & Weekly Breakout Stock Alerts - Newser
What does recent volatility data suggest for Kura Oncology Inc.2025 Price Targets & Entry Point Confirmation Alerts - Newser
Why Kura Oncology Inc. is moving todayJuly 2025 Institutional & Weekly High Potential Stock Alerts - Newser
Kura Oncology Inc (KURA Stock: A Sea of Opportunity - investchronicle.com
Kura Oncology Gains 32%, Insider Trades Reap Benefit - simplywall.st
Chart based analysis of Kura Oncology Inc. trendsJuly 2025 Retail & Free High Return Stock Watch Alerts - Newser
Analyzing Kura Oncology Inc. with multi timeframe charts2025 Buyback Activity & Target Return Focused Picks - Newser
What high frequency data says about Kura Oncology Inc.2025 Major Catalysts & Safe Capital Growth Trade Ideas - Newser
Order flow analysis tools used on Kura Oncology Inc.Earnings Risk Summary & Real-Time Volume Analysis Alerts - Newser
Kura Oncology (NASDAQ:KURA) Shares Gap Up – Still a Buy? - Defense World
Is Kura Oncology Inc. stock entering bullish territoryTreasury Yields & Long-Term Growth Plans - Newser
Wall Street Zen Upgrades Kura Oncology (NASDAQ:KURA) to “Hold” - Defense World
Using Bollinger Bands to evaluate Kura Oncology Inc.July 2025 Retail & AI Forecasted Entry and Exit Points - Newser
What makes Kura Oncology Inc. stock price move sharply2025 Macro Impact & Weekly Watchlist for Consistent Profits - Newser
CEO Buy-In and Analyst Optimism at Kura Oncology: A Strategic Opportunity in Oncology Innovation - AInvest
Quant Strategy Flags Kura Oncology Inc. for EntryMarket Performance Recap & Safe Swing Trade Setup Alerts - metal.it
How hedge fund analytics apply to Kura Oncology Inc. stockMarket Trend Report & Verified Stock Trade Ideas - Newser
Kura Oncology Inc. stock chart pattern explainedJuly 2025 Final Week & AI Driven Stock Movement Reports - Newser
Kura Oncology Shares Rise After CEO Buys Company Shares - MarketScreener
Why Kura Oncology (KURA.O) Spiked 14% on a Quiet Day — A Technical Deep Dive - AInvest
Kura Oncology Surges 13.18%—What's Really Behind the Intraday Move? - AInvest
Multi asset correlation models including Kura Oncology Inc.July 2025 Sector Moves & Daily Volume Surge Signals - Newser
US Bancorp DE Acquires 17,523 Shares of Kura Oncology, Inc. (NASDAQ:KURA) - Defense World
Kura Oncology’s CEO Makes a Bold Move with Significant Stock Purchase - TipRanks
Price Consolidation Hints at Upcoming Move in Kura Oncology Inc.2025 Fundamental Recap & Weekly Setup with ROI Potential - 선데이타임즈
JMP Securities Lowers Kura Oncology Price Target to $24, Maintains Market Outperform Rating - AInvest
Analysts Weigh In on 10x Genomics, Kura Oncology and Insulet: Buy or Hold? - AInvest
JMP Securities Has Lowered Expectations for Kura Oncology (NASDAQ:KURA) Stock Price - Defense World
Kura Oncology’s Earnings Call: Progress Amidst Challenges - TipRanks
Kura Oncology, Inc. (NASDAQ:KURA) Q2 2025 Earnings Call Transcript - Insider Monkey
Why Kura Oncology Inc. stock attracts strong analyst attentionDouble in 10 Days Stock Ideas - newsyoung.net
Kura Oncology’s SWOT analysis: ziftomenib’s potential drives stock outlook - Investing.com
Kura Oncology’s SWOT analysis: ziftomenib’s potential drives stock outlook By Investing.com - Investing.com Nigeria
Wedbush Has Bearish Forecast for Kura Oncology Q1 Earnings - Defense World
Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
JMP Securities Maintains Market Outperform on Kura Oncology with New PT of $24 - AInvest
Kura Oncology stock price target lowered to $24 at Citizens JMP - Investing.com Canada
What candlestick patterns are forming on Kura Oncology Inc.Free Pattern Detection for Entry Confirmation - Newser
Kura Oncology price target lowered to $27 from $29 at BofA - TipRanks
Kura Oncology, Inc. (NASDAQ:KURA) Just Reported And Analysts Have Been Cutting Their Estimates - Yahoo Finance
Kura Oncology Reports Q2 2025 Earnings: Key Takeaways - AInvest
Candlestick Reversal Detected on Kura Oncology Inc.’s ChartStrong Buy With Technical Confidence Supported - beatles.ru
How to escape a deep drawdown in Kura Oncology Inc.Market Downturn Defense Strategy Analysis - Newser
Kura Oncology shares fall 5.12% intraday despite FDA Priority Review of ziftomenib NDA. - AInvest
Kura Oncology’s Promising Future: Strong Financials and Advancements in AML Treatment Drive Buy Rating - TipRanks
Earnings call transcript: Kura Oncology Q2 2025 shows revenue miss, EPS below forecast By Investing.com - Investing.com South Africa
Kura Oncology Inc Stock (KURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kura Oncology Inc Stock (KURA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| WILSON TROY EDWARD | President and CEO |
Aug 13 '25 |
Buy |
6.64 |
13,494 |
89,623 |
50,968 |
| Bair Teresa Brophy | Chief Legal Officer |
May 19 '25 |
Sale |
5.96 |
1,559 |
9,292 |
107,948 |
| FORD KATHLEEN | Chief Operating Officer |
May 19 '25 |
Sale |
6.28 |
1,558 |
9,777 |
21,367 |
1.34%
0.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):